COVID-19 Review Volume 12, Issue 23 pp 24462—24474
Clinical challenges in cancer patients with COVID-19: Aging, immunosuppression, and comorbidities
- 1 Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- 2 Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- 3 Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Received: August 4, 2020 Accepted: September 6, 2020 Published: November 24, 2020
https://doi.org/10.18632/aging.104205How to Cite
Copyright: © 2020 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
COVID-19 caused by severe acute respiratory syndrome coronavirus 2 has developed into a global pandemic. COVID-19 poses a huge threat to health care, and the shortage of medical resources caused by COVID-19 brought serious secondary disasters to elderly cancer patients who are particularly dependent on medical resources. The clinical challenges of cancer management, including aging, immunosuppression, and comorbidities, make cancer patients more vulnerable to COVID-19 with different clinical manifestations, disease severity, and outcomes. The review comprehensively analyzed the characteristics of the cancer patients under the pandemic and concluded that cancer patients were more susceptible to COVID-19, and also concluded that they were more likely to develop poor outcomes and the severe form of the disease. Three basic management strategies have been proposed to protect susceptible elderly cancer patients, find reliable indicators to monitor the course of disease, and implement effective prevention measures.
Abbreviations
COVID-19: coronavirus disease-2019; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; NT-proBNP: N terminal pro B type natriuretic peptide; TMPRSS2: transmembrane serine protease 2; TNF-α: tumor necrosis factor-alpha; IL-6: interleukin-6; ICU: intensive care unit; CT: computed tomography; CD4: cluster of differentiation 4; SARS: severe acute respiratory syndrome; ECOG PS: Eastern Cooperative Oncology Group Performance Status; ACE2: angiotensin converting enzyme 2; CDC: centers for disease control and prevention.